Howe & Rusling’s NovoCure NVCR Stock Holding History

Howe & Rusling’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-23	Closed	-$1K	–	852
2019 Q2	$1K	Hold	23	–	–	﹤0.01%	756
2019 Q1	$1K	Hold	23	–	–	﹤0.01%	756
2018 Q4	$1K	Buy	+23	New	+$841	﹤0.01%	758

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Howe & Rusling's NVCR Position: Q3 2019 in Review

Howe & Rusling sold out of NovoCure (NVCR) in Q3 2019, closing a stake of 23 shares — an estimated $1K sold.

Howe & Rusling first reported a position in NVCR in Q4 2018 and held it in 3 quarters. The position peaked at $1K in Q2 2019. 240 funds tracked by Wall St. Rank hold NVCR as of Q3 2019.

Howe & Rusling reported no remaining NovoCure position as of Q3 2019 after selling out during the quarter.
Howe & Rusling sold 23 NovoCure shares in Q3 2019, an estimated $1K.
Howe & Rusling first reported a position in NovoCure in Q4 2018 and held it in 3 quarters.
Howe & Rusling's NovoCure position peaked at $1K in Q2 2019.
240 funds tracked by Wall St. Rank held NovoCure as of Q3 2019.

Based on Howe & Rusling's 13F filing for Q3 2019, filed 31 Oct 2019.